| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8439284 | European Journal of Cancer | 2018 | 8 Pages |
Abstract
Resection of MCC BM may confer a survival benefit given appropriate patient selection. Prospective investigation of multimodal management of neurometastatic MCC is warranted, especially given the promise of new immunotherapy agents in treating MCC.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Maya Harary, Vasileios K. Kavouridis, Manisha Thakuria, Timothy R. Smith,